» Articles » PMID: 19842104

Anti-obese Property of Fucoxanthin is Partly Mediated by Altering Lipid-regulating Enzymes and Uncoupling Proteins of Visceral Adipose Tissue in Mice

Overview
Date 2009 Oct 21
PMID 19842104
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

This study investigated the anti-obesity effects of fucoxanthin in diet-induced obesity mice fed a high-fat diet (20% fat, wt/wt). The mice were supplemented with two doses of fucoxanthin (0.05 and 0.2%, wt/wt) for 6 wk. Fucoxanthin significantly lowered body weight and visceral fat-pads weights compared with the control group without altering food intake. In epididymal adipose tissue of fucoxanthin-fed mice, adipocyte sizes and mRNA expression of lipogenic and fatty acid beta-oxidation enzymes were significantly altered in a dose-dependent manner. Plasma leptin level was significantly lower in the fucoxanthin groups than in the control group, while the adiponectin level was elevated. Fucoxanthin significantly down-regulated various lipogenic enzyme activities in epididymal adipose tissue with a simultaneous decrease in fatty acid beta-oxidation activity. The 0.2% fucoxanthin supplement led to increase mRNA expression of uncoupling protein-1 (UCP-1) and UCP-3 in brown adipose tissue and that of UCP-2 in the epididymal white adipose tissue. However, the 0.05% fucoxanthin only elevated UCP-1 mRNA expression in epididymal white adipose tissue. These results suggest that the anti-obesity effect of fucoxanthin could be mediated by altering lipid-regulating enzymes and UCPs in the visceral fat tissues and plasma adipokine levels.

Citing Articles

Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue.

Gong D, Lei J, He X, Hao J, Zhang F, Huang X Lipids Health Dis. 2024; 23(1):322.

PMID: 39342273 PMC: 11439242. DOI: 10.1186/s12944-024-02300-z.


Unlocking the Green Gold: Exploring the Cancer Treatment and the Other Therapeutic Potential of Fucoxanthin Derivatives from Microalgae.

Mohamed Abdoul-Latif F, Ainane A, Houmed Aboubaker I, Merito Ali A, Mohamed H, Jutur P Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065808 PMC: 11280058. DOI: 10.3390/ph17070960.


Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?.

Andres C, Perez de la Lastra J, Munguira E, Juan C, Perez-Lebena E Int J Mol Sci. 2024; 25(11).

PMID: 38892287 PMC: 11172677. DOI: 10.3390/ijms25116099.


Marine Compounds and Age-Related Diseases: The Path from Pre-Clinical Research to Approved Drugs for the Treatment of Cardiovascular Diseases and Diabetes.

Giuliani M, Bigossi G, Lai G, Marcozzi S, Brunetti D, Malavolta M Mar Drugs. 2024; 22(5).

PMID: 38786601 PMC: 11123485. DOI: 10.3390/md22050210.


Effects of N-acetylcysteine on the expressions of UCP1 and factors related to thyroid function in visceral adipose tissue of obese adults: a randomized, double-blind clinical trial.

Sohouli M, Eslamian G, Ardehali S, Raeissadat S, Shimi G, Pourvali K Genes Nutr. 2024; 19(1):8.

PMID: 38702594 PMC: 11069202. DOI: 10.1186/s12263-024-00744-7.